{"id":"apo-go","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4297466","moleculeType":"Protein","molecularWeight":"2352.82"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APO-go works by releasing iron from the drug, which is then absorbed by the body to treat iron deficiency anemia. It is a type of oral iron replacement therapy.","oneSentence":"APO-go is a medication used to treat iron deficiency anemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:45.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of iron deficiency anemia"}]},"trialDetails":[{"nctId":"NCT03391882","phase":"PHASE3","title":"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-12-19","conditions":"Motor OFF Episodes Associated With Parkinson's Disease","enrollment":113},{"nctId":"NCT03623828","phase":"PHASE2","title":"Treating Severe Brain-injured Patients With Apomorphine","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2018-10-03","conditions":"Disorder of Consciousness","enrollment":8},{"nctId":"NCT03292016","phase":"PHASE2","title":"A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by \"OFF\" Episodes","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-08-22","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT02006121","phase":"PHASE3","title":"Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2014-03-03","conditions":"Parkinson's Disease","enrollment":107},{"nctId":"NCT00758368","phase":"PHASE2","title":"Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02702076","phase":"PHASE2","title":"Apomorphine in Parkinson's Disease Patients With Visual Hallucinations","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2017-05","conditions":"Parkinson's Disease, Hallucinations, Visual","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amomorphine"],"phase":"phase_2","status":"active","brandName":"APO-go","genericName":"APO-go","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APO-go is a medication used to treat iron deficiency anemia. Used for Treatment of iron deficiency anemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}